1. Introduction {#s0005}
===============

The prevalence of atrial fibrillation (AF) increases with aging in Japan [@bib1]. An epidemiological survey conducted by the Japanese Circulation Society indicated that the prevalence of AF was gradually increasing, and estimated a prevalence rate of 0.79% by 2020 [@bib2]. The results of cohort-based [@bib3] and community-based [@bib4] surveys showed that the prevalence of AF in Japan is already \>1%.

AF is an important risk factor for stroke. The incidence of stroke in patients with nonvalvular AF (NVAF) was reported to be about 5% per year, and 2- to 7-fold higher than in the population without AF [@bib5], [@bib6]. The result of a Japanese study indicated that, among 15,831 patients hospitalized with acute cerebral infarction, AF was observed in 3335 patients, 78.4% of whom were found to have cardiogenic embolism [@bib7]. Medical treatment in patients with AF should thus also be targeted at preventing cerebral thrombosis/embolism, as well as other types of embolisms.

Antithrombotic treatment is important for preventing stroke in patients with NVAF, and warfarin and anticoagulants have been the recommended treatments; additionally, aspirin and antiplatelet preparations have been acceptable. The Japanese Guidelines for Treatment of Stroke 2009 [@bib8] recommended warfarin for managing NVAF patients with more than two risk factors (congestive heart failure, hypertension, age \>75 years, or diabetes mellitus), whereas antiplatelet preparations are acceptable in patients with contraindications to warfarin. Additionally, the latest Japanese Guidelines for Pharmacotherapy of Atrial Fibrillation [@bib9] addressed the importance of many risk factors when selecting suitable antithrombotic drug therapies such as warfarin, in accordance with the severity of the risk.

In March 2011, the new oral direct thrombin inhibitor (DTI) dabigatran, with a novel mechanism of action, was introduced on the market [@bib10], and a new drug application for the factor Xa inhibitor rivaroxaban was filed in 2011. These drugs are superior, or at least not inferior, to warfarin in terms of efficacy and safety [@bib11], [@bib12], and are therefore likely to change the standard of antithrombotic therapy in the near future.

The aim of this cross-sectional study was to investigate the relationships between patient characteristics and antithrombotic therapy prescribed for the prevention of ischemic stroke and systemic embolism in patients with NVAF in clinical practice. Additionally, because the data were to be used to compare with the characteristic data of postmarketing surveillance (PMS) for dabigatran by Nippon Boehringer Ingelheim [@bib13], which was performed in parallel to this study, patients prescribed with dabigatran were excluded from this study.

2. Material and methods {#s0010}
=======================

This was a cross-sectional study carried out to investigate the characteristics, treatments, and pathological backgrounds of patients with NVAF treated for the prevention of ischemic stroke. Surveillance was performed from October 2011 to March 2014 (entry of patients: April 2012 to December 2013) at 268 medical sites that participated in the PMS for dabigatran throughout Japan. Patients with NVAF who received antithrombotic treatments to prevent ischemic stroke were registered. Site investigators collected the patient data from medical records at the first visit after registration.

2.1. Subjects {#s0015}
-------------

Adult patients with AF, regardless of sex, complications, hospitalization, or medical history, who received antithrombotic treatment to prevent a cerebrovascular ischemic attack, were enrolled in this study. The exclusion criteria were (i) patients who received artificial valve replacement, (ii) those with valvular disease, (iii) those with DTI preparation (dabigatran) use, and (iv) those without antithrombotic treatment.

2.2. Surveillance method {#s0020}
------------------------

Patient characteristics, AF history and characteristics, comorbidity, and history of antithrombotic treatment were obtained from medical records and transcribed into an electrical case report by the site investigators. The collected characteristics included sex, date of birth, body weight, height, smoking history, and alcohol consumption. The AF history and characteristics included onset date, symptomatic or asymptomatic status, type of AF, and treatment including surgical intervention. Comorbidity included congestive heart failure, hypertension, diabetes mellitus, stroke, transient ischemic attack (TIA), systemic embolism, pulmonary embolism, peripheral artery diseases (arteriosclerosis obliterans, chronic arterial occlusion), dyslipidemia (hyperlipidemia), angina pectoris, myocardial infarction (MI), valvular disease, renal dysfunction including impaired creatinine clearance calculated by using the Cockcroft--Gault method [@bib14], hepatic diseases, dementia, and bleeding events. Information was collected on current antithrombotic treatments and withdrawn treatments before this study. The start and end dates of administration, dosage of anticoagulant (warfarin, dabigatran, rivaroxaban, heparin, other non-oral anticoagulant \[non-OACs\]), and antiplatelet preparations (aspirin, ticlopidine, cilostazol, clopidogrel, eicosapentaenoic acid ethylate, beraprost sodium, sarpogrelate hydrochloride, and others) were included. Details on concomitant use of angiotensin II receptor blockers (ARB), angiotensin-converting enzyme inhibitors, beta-blockers, antihypertensives, insulin, oral hypoglycemics, and statins were also collected. The prothrombin time--international normalized ratio (PT--INR) within 3 months before visit was recorded for patients treated with warfarin, if available. The study protocol and provision of information to participants were carried out in line with the ethical guidelines for epidemiological research (established by the Ministry of Health, Labour, and Welfare in Japan) and approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (September 28, 2011; no. E1220). No medical intervention and no biological specimens from human subjects were specified in this study; therefore, verbal and/or anonymized information and consent were acceptable, as well as written informed consent. This study was registered to UMIN Clinical Trial Registry (no. 000009644).

2.3. Statistical analysis {#s0025}
-------------------------

For primary analysis, we classified the patients according to their antithrombotic regimen: antiplatelet monotherapy (AP), anticoagulant monotherapy (AC), and concomitant use of antiplatelet and anticoagulant (AP+AC). Patient characteristics, AF history and characteristics, comorbidity, and history of antithrombotic treatment were tabulated for each group and compared among the three groups. The measured values and order values are shown as means and standard deviations (SDs) in the tables, and *P* values were calculated by using ANOVA adjusted by sex and age, in 10-year steps. Nominal scale values are shown as frequencies and proportions, and *P* values were calculated by using the Cochran--Mantel--Haenszel method adjusted by sex and age. The pair-wise test for the factor with a statistical difference among the three groups was performed under a closed testing procedure as adjusted for multiplicity. Multivariate analysis was performed through multiple multinomial logit analysis with the above items as independent variables, and variable selection in the model by using a stepwise method.

Additionally, we further classified patients taking OACs (AC and AP+AC) into the following three groups: naïve (N) patients with an OAC regimen initiated within 6 months before the observation date and not changed; switchers (S), in whom OACs were changed within 6 months before the observation date; and prevalent users (P), who continued the use of the same OAC for \>6 months before the observation date. We also classified patients taking OACs into warfarin users and rivaroxaban users, for reference. The patient distribution in the treatment history of OACs was also compared by using the analysis methods. A two-sided *P* value of ≤0.05 was considered significant. The statistical analysis was performed by using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

3. Results {#s0030}
==========

3.1. Primary analysis {#s0035}
---------------------

A total of 3138 patients from 274 medical sites were initially registered to this study. Eighty-five patients were ineligible because of not meeting the inclusion or exclusion criteria: patients with no antithrombotic treatment (*n*=17), with dabigatran treatment (*n*=4), with mitral valve stenosis (*n*=21) and those who underwent mitral valve replacement (*n*=46; 10 patients with mitral valve stenosis), with no detailed information on OACs (*n*=1), with input error (*n*=5), and with duplicated case registration (*n*=1). The remaining 3053 patients included 216 (7.1%) in the AP group, 2381 (78.0%) in the AC group, and 456 (14.9%) in the AP+AC group. The main antithrombotic regimens were warfarin (*n*=2523; mean±SD daily dose: 2.70±1.10 mg), aspirin (*n*=479, 99.5±13.9 mg), rivaroxaban (*n*=311, 12.2±2.5 mg), clopidogrel (*n*=122, 71.9±8.2 mg), and cilostazol (*n*=59, 152.6±56.8 mg).

ARBs (*n*=1391), beta-blockers (*n*=1145), statins (*n*=873), or antiarrhythmic drugs (*n*=794) were administered concomitantly with antithrombotic drugs. The pharmacological regimens in each group are shown in [Table 1](#t0005){ref-type="table"}.

### 3.1.1. Patient characteristics {#s0040}

The patient characteristics are shown in [Table 2](#t0010){ref-type="table"}. There were significant differences in sex, age, smoking history, prevalence periods of AF, and type of AF among the three groups. According to the results of multiple multinomial logit analysis, the proportion of men was lower in the AC group than in the AP+AC group. The mean age was also lower in the AC group than in the AP+AC group (73.7 and 75.9 years, respectively). The mean prevalence period of AF was longer in the AP+AC group than in the AP or AC group (5.09, 4.10, and 4.40 years, respectively). The proportion of permanent type of AF was higher in the AP+AC group than in the AP group. There were no significant differences in characteristics between the AP group and the AC group ([Supplementary Table S1](#s0090){ref-type="sec"}).

### 3.1.2. CHADS~2~ and comorbidity {#s0045}

The mean CHADS~2~ score in the AP+AC group (2.7±1.4) was significantly higher than that in the AP group (2.0±1.3) or AC group (2.1±1.3) ([Table 3](#t0015){ref-type="table"}). A total of 32.5% of patients had scores of 0 or 1, although only 20.8% of the patients in the AP+AC group had low scores. In contrast, a higher proportion of patients in the AP+AC group (27.1%) had scores ≥4 compared with the other two groups (12.1% in AP, 13.8% in AC). The results of multiple multinomial logit analysis excluded the six composite factors of the CHADS~2~ score (age, heart failure, hypertension, diabetes, stroke, and TIA). The CHADS~2~ score in the AP+AC group was statistically higher than that in the AP group or AC group ([Supplementary Table S2](#s0090){ref-type="sec"}).

The main comorbidity is also shown in [Table 3](#t0015){ref-type="table"}. There were significant differences in comorbidity among the three groups, except in terms of pulmonary thromboembolism, hepatic insufficiency, and bleeding history. The prevalence rate of heart failure was significantly higher in the AP+AC group than in the AP group and the AC group, and higher in the AC group than in the AP group. The prevalence rates of stroke and MI were higher in the AP+AC group than in the AP group and the AC group. The prevalences of peripheral artery diseases and angina were lower in the AC group than in the AP+AC group or the AP group. The prevalence of renal sufficiency was lower in the AC group than in the AP+AC group or the AC group.

The prevalences of TIA and dyslipidemia were lower in the AC group than in the AP+AC group ([Supplementary Table S2](#s0090){ref-type="sec"}).

### 3.1.3. Bleeding events {#s0050}

A total of 139 bleeding events were reported, for which 109 patients were prescribed an antithrombotic regimen ([Table 4](#t0020){ref-type="table"}). The regimens for bleeding events were AP monotherapy in 9 (7.3%), AC monotherapy in 79 (72.5%), and AP+AC therapy in 22 (20.2%) patients. AP monotherapy was changed to AC monotherapy in 5 patients and AP+AC in 3 patients at the observation point, whereas AC monotherapy was changed to AP monotherapy in 3 patients and AP+AC in 8 patients, and was continued in the remaining 68 patients. Among the 22 AP+AC patients, 11 continued and 11 discontinued the AP regimen. This switching of antithrombotic drugs was not significant in Bowker's test.

3.2. Subanalysis for OAC regimens {#s0055}
---------------------------------

Among the 2837 patients in the AC and AP+AC groups, six were excluded from analysis because of monotherapy with non-OACs at the observation point. Among the remaining 2831 patients, there were 328 in the N group, 213 in the S group, and 2290 in the P group ([Table 5](#t0025){ref-type="table"}). In the N group, 216 patients received warfarin and 112 received rivaroxaban ([Table 7](#t0035){ref-type="table"}). In the P group, warfarin was administered in 2252 patients, rivaroxaban in 36 patients, and warfarin and rivaroxaban concomitantly in 3 patients. The regimens in the S group were rivaroxaban switched to warfarin in 4 patients, dabigatran to warfarin in 48 patients, warfarin to rivaroxaban in 91 patients, and dabigatran to rivaroxaban in 70 patients.

The patient characteristics, CHADS~2~ scores, comorbidity, creatinine clearance, and PT--INR stratified to warfarin users (*n*=2520) and rivaroxaban users (*n*=308) are shown in [Supplementary Table S3](#s0090){ref-type="sec"}. There were significant differences in sex, body weight, smoking history, alcohol history, CHADS~2~ score, prevalence periods, comorbidity (heart failure, hypertension, diabetes, peripheral artery diseases, and angina), and creatinine clearance.

### 3.2.1. Patient characteristics {#s0060}

There were significant differences in terms of sex, body weight, body mass index (BMI), prevalence period of AF, and type of AF among the three groups ([Table 5](#t0025){ref-type="table"}). The results of multiple multinomial logit analysis showed that the proportion of female patients was higher in the N group than in the P group, BMI was higher in the P group than in the N or S group, and the proportion of persistent/paroxysmal AF types was higher in the N group than in the P group.

### 3.2.2. CHADS~2~ and comorbidity {#s0065}

The CHADS~2~ scores were similar in all three groups ([Table 6](#t0030){ref-type="table"}). In terms of comorbidity, the rate of dyslipidemia, dementia, and bleeding history were significant among the three groups. In the results of multiple multinomial logit analysis, the prevalences of heart failure and angina were significantly lower in the N group than in the P group, peripheral artery diseases were significantly higher in the N group than in the P or S group, and bleeding history was higher in the S group than in the P or N group ([Supplementary Table S4](#s0090){ref-type="sec"}).

### 3.2.3. Daily dose of anticoagulants and PT--INR {#s0070}

The mean (±SD) daily doses of warfarin were 2.44±1.09 mg in the N group, 2.47±1.03 mg in the S group, and 2.73±1.10 mg in the P group (*P=*0.002), whereas the daily doses of rivaroxaban were 12.50±2.51, 11.96 ± 2.45, and 12.50±2.53 mg, respectively (*P=*0.2652). The mean (±SD) PT--INR values were only measured in patients receiving warfarin, and were 1.83±0.47 in the N group, 2.01±0.44 in the S group, and 2.00±0.43 in the P group (*P*\<0.0001) ([Table 7](#t0035){ref-type="table"}).

4. Discussion {#s0075}
=============

The patient characteristics, CHADS~2~, and comorbidity in the current study population were similar to those in other Japanese reports [@bib4], [@bib15], suggesting that the sample well reflected the Japanese AF population. We investigated the differences in characteristics, CHADS~2~, and comorbidity among patients prescribed the AP, AC, and AP+AC regimens, to identify the factors determining the choice of regimen. Antithrombotic treatment for patients with NVAF is generally based on anticoagulant preparations, especially warfarin. In this study, there were significant differences in sex, age, smoking history, prevalence period of AF, type of AF, CHADS~2~ scores, and most comorbidities among the three regimens. Specifically, the proportion of male patients, age, and the prevalence periods of AF were higher in the AP+AC group than in the AC group in multiple analysis. Additionally, the prevalence periods of AF and the ratio of permanent/paroxysmal AF types were higher in the AP+AF group than in the AP group. In contrast, there were no differences between the two monotherapy groups. These results suggest that patient characteristics are not the factors for selecting AP or AC monotherapy, but are the factors for adding a combination drug. The average and the classification of the CHADS~2~ scores are also significant among the three groups. In the AP+AC group, the CHADS~2~ score was higher than that in the AP group or the AC group; nevertheless, there were no differences between the AP group and the AC group. The comorbidity of cardiovascular risk factors (heart failure, hypertension, stroke, TIA, systematic thromboembolism, pulmonary thromboembolism, deep vein thrombosis, peripheral artery diseases, angina, and MI) were significant among the three groups. The prevalence rates of heart failure and MI were higher in the AP+AC group than in the AP group, and heart failure, stroke, TIA, peripheral artery diseases, dyslipidemia, angina, and MI were higher in the AP+AC group than in the AC group. On the other hand, AP monotherapy was higher in the treatment of peripheral artery diseases and angina than AC monotherapy. These findings suggest that combination therapy is preferentially adopted in AF complicated by other diseases with thrombotic risk. AP monotherapy was adopted in comorbidities caused by atherosclerosis such as angina. These results show that practitioners prescribe antithrombotic agents in line with the recommendations in the cardiovascular guidelines for stroke, MI, AF, and antithrombotic treatment for cardiovascular diseases [@bib8], [@bib9], [@bib16], [@bib17].

We performed a secondary analysis to investigate the common use of OACs. Warfarin (*n*=2520) and rivaroxaban (n=308) were administered. There were significant differences in factors such as sex, CHADS~2~ score, heart failure, hypertension, diabetes, and angina and creatinine clearance. These results show that rivaroxaban is prescribed in AF patients with lower risks rather than warfarin. We stratified all patients with anticoagulant treatment into the N, S, and P groups. These results showed a high proportion of women (43.6%) among the naïve patients compared with those in other reports [@bib7], [@bib15], suggesting a recent increase in the incidence of female patients with AF. BMI was higher in the P group than in the N and S groups; however, the clinical relevance of this is unclear. There was no statistical difference among the three groups in the CHADS~2~ score. With regard to the comorbidity, the prevalence rates of heart failure and angina were lower in the N group than in the P group. Conversely, the prevalence rate of peripheral artery diseases was higher in the N group than in the P or S group. Only bleeding history was higher in the S group than in the other two groups. These findings suggest that the switching of anticoagulant agents was unaffected by patient characteristics, CHADS~2~ score, and comorbidity, but was influenced by bleeding history.

AC regimens have also demonstrated better preventive effects in terms of stroke than AP regimens [@bib18], [@bib19], [@bib20], whereas major or minor bleeding events in Japanese patients with cardiovascular diseases were reported to be more frequent in patients taking AC than in those taking AP regimens [@bib21]. To understand the risk/benefit balance on antithrombotic therapy in actual treatment, we investigated the change of antithrombotic regimens in cases in which bleeding events occurred. After experiencing bleeding events, 62.5% of patients with AP monotherapy changed to AC and 37.5% to AP+AC, whereas among AP+AC patients, 50% changed to AC monotherapy. Conversely, among patients with AC monotherapy, only 13.9% patients changed to AP or AP+AC regimens. AC monotherapy was continued for 86.1% of patients.

These changes of antithrombotic regimens were not significant; therefore, unfortunately, we cannot conclude the relation of the change of regimens with bleeding events.

The PT--INR was lower in N patients than in S or P patients (1.83, 2.01, and 2.00, respectively). These values are included in the recommended lowest relative risk value for ischemic stroke and intracranial hemorrhage for Japanese patients [@bib15].

In conclusion, the presence of atherosclerotic diseases such as angina and peripheral artery diseases is a major factor determining the selection of antithrombotic monotherapy, and the CHADS~2~ score and comorbidity are major factors determining the combination regimen with AP and AC. Bleeding history was not a factor determining antithrombotic therapy. Conversely, bleeding history is the major factor determining the selection of OACs in Japan.

This study was limited by the lack of information on the economic background and treatment preference of patients. In addition, it was limited by the exclusion of dabigatran users. The patient characteristics in European and US studies [@bib22], [@bib23] showed differences between patients using warfarin and dabigatran regimens, such as in terms of CHADS~2~ scores and comorbidities. We therefore intend to compare our results with the PMS background data for dabigatran.
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###### 

Antithrombotic and other drugs at the observation point.

Table 1

                                   Antithrombotic drugs   Total                                                                          
  -------------------------------- ---------------------- ------------ ------------- ----------- ------------ ------------ ------------- ------------
  Total                            216                                 2381                      456                       3053          
  Antithrombotic drugs                                                                                                                   
  *Warfarin*                       --                                  2095 (88.0)   2.71±1.11   428 (93.9)   2.64±1.07    2523 (82.6)   2.70±1.10
  *Rivaroxaban*                    --                                  283 (11.9)    12.3±2.5    28(6.1)      11.4±2.3     311 (10.2)    12.2±2.5
  *Heparin*                        --                                  2 (0.1)                                             2 (0.1)       
  *Other non-oral anticoagulant*   --                                  6 (0.3)                                             6(0.2)        
  *Aspirin*                        150 (69.4)             99.8±10.8    --                        329 (72.2)   99.3±13.9    479 (15.7)    99.5±13.0
  *Ticlopidine*                    6 (2.8)                150.0±54.8   --                        23 (5.0)     173.9±44.9   29 (0.9)      169.0±47.1
  *Cilostazol*                     12 (5.6)               154.2±58.2   --                        47 (10.3)    152.2±57.0   59 (1.9)      152.6±56.8
  *Clopidogrel*                    43 (19.9)              70.4±9.8     --                        79 (17.3)    72.8±7.2     122 (4.0)     71.9±8.2
  Antihypertensive drugs           160 (74.1)                          1759 (73.9)               365 (80.0)                2284 (74.8)   
  *ARBs*                           89 (41.2)                           1078 (45.3)               224 (49.1)                1391 (45.6)   
  *ACEIs*                          16 (7.4)                            204 (8.6)                 41 (9.0)                  261 (8.5)     
  *Beta-blockers*                  66 (30.6)                           901 (37.8)                178 (39.0)                1145 (37.5)   
  Antiarrhythmic drugs             53 (24.5)                           628 (26.4)                113 (24.8)                794 (26.0)    
  Oral hypoglycemia                24 (11.1)                           322 (13.5)                88 (19.3)                 434 (14.2)    
  Statin                           69 (31.9)                           618 (26.0)                186 (40.8)                873 (28.6)    

AP, antiplatelet monotherapy; AC, anticoagulant monotherapy; ARBs, angiotensin II receptor blockers; ACEIs, angiotensin-converting enzyme inhibitors.

Data are *n* (%).

Doses are in mg/day; mean±SD.

###### 

Characteristics of patients according to regimen.

Table 2

                                         AP            AC            AP+AC         *P*-value[a](#tbl2fna){ref-type="table-fn"}   Total                                  
  -------------------------------------- ------------- ------------- ------------- --------------------------------------------- ------------- ------ ---------- ------ ------
  Total                                  216                         2381                                                        456                             3053   
  **Sex**                                                                                                                                                               
  Male                                   150           69.4          1540          64.7                                          327           71.7   0.0005     2017   66.1
  Female                                 66            30.6          841           35.3                                          129           28.3              1036   33.9
  **Age (years)**                                                                                                                                                       
  Mean (SD)                              74.1 (9.9)    73.7 (9.7)    75.9 (7.9)    \<0.0001                                      74.1 (9.5)                             
  \<65                                   34            15.7          404           17.0                                          37            8.1    \<0.0001   475    15.6
  65--\<75                               78            36.1          874           36.7                                          181           39.7              1133   37.1
  75--                                   104           48.1          1103          46.3                                          238           52.2              1445   47.3
  **Body weight (kg)**                                                                                                                                                  
  Mean (SD)                              60.9 (12.1)   61.1 (12.4)   61.7 (11.7)   0.5751                                        61.2 (12.3)                            
  **BMI (kg/m**^**2**^**)**                                                                                                                                             
  Mean (SD)                              23.6 (3.7)    23.7 (3.6)    23.9 (3.4)    0.3358                                        23.7 (3.6)                             
  **Prevalence periods of AF (years)**                                                                                                                                  
  Mean (SD)                              4.10 (3.36)   4.40 (3.12)   5.09 (3.29)   0.0054                                        4.48 (3.17)                            
  **Type of AF**                                                                                                                                                        
  Paroxysmal                             80            37.0          788           33.6                                          132           30.0   0.0058     1000   33.3
  Persistent                             59            27.3          455           19.4                                          97            22.0              611    20.4
  Permanent                              77            35.6          1100          46.9                                          211           48.0              1388   46.3
  **Smoking history**                                                                                                                                                   
  Nonsmoker                              98            52.1          1323          62.5                                          215           55.4   0.0430     1636   60.8
  Ex-smoker                              76            40.4          610           28.8                                          137           35.3              823    30.6
  Smoker                                 14            7.4           184           8.7                                           36            9.3               234    8.7
  **Alcohol consumption (g/week)**                                                                                                                                      
  None                                   90            49.5          1149          55.4                                          215           56.0   0.5478     1454   55.1
  \<14                                   30            16.5          244           11.8                                          39            10.2              313    11.9
  14--\<112                              37            20.3          373           18.0                                          74            19.3              484    18.3
  \>112                                  25            13.7          307           14.8                                          56            14.6              388    14.7

AP, antiplatelet monotherapy; AC, anticoagulant monotherapy; AF, atrial fibrillation; BMI, body mass index.

*P*-values were calculated by using the Cochran--Mantel--Haenszel test adjusted by sex and age for classification (sex, type of AF, smoking history, and alcohol history) and order (age) values, and ANOVA adjusted by sex and age for measured values (age, body weight, BMI, and prevalence periods of AF).

###### 

CHADS~2~ scores, comorbidity, creatinine clearance, and PT--INR according to regimen.

Table 3

                                  AP            AC            AP+AC         *P*-value[a](#tbl3fna){ref-type="table-fn"}   Total                                  
  ------------------------------- ------------- ------------- ------------- --------------------------------------------- ------------- ------ ---------- ------ ------
  **CHADS**~**2**~**score**                                                                                                                                      
  Mean (SD)                       2.0 (1.3)     2.1 (1.3)     2.7 (1.4)     \<0.0001                                      2.2 (1.3)                              
  0                               22            10.3          212           9.0                                           23            5.1    \<0.0001   257    8.5
  1                               58            27.1          596           25.3                                          71            15.7   725        24.0   
  2                               65            30.4          739           31.3                                          104           23.1   908        30.0   
  3                               43            20.1          486           20.6                                          131           29.0   660        21.8   
  4                               16            7.5           230           9.7                                           81            18.0   327        10.8   
  5                               10            4.7           77            3.3                                           28            6.2    115        3.8    
  6                               0             0.0           19            0.8                                           13            2.9    32         1.1    
                                                                                                                                                                 
  **Comorbidity**                                                                                                                                                
  Heart failure                   51            23.7          766           32.3                                          190           41.9   \<0.0001   1007   33.1
  Hypertension                    160           74.1          1605          67.6                                          329           72.5   0.0328     2094   68.8
  Diabetes                        47            21.9          520           21.9                                          139           30.6   0.0007     706    23.2
  Stroke                          34            15.7          441           18.5                                          153           33.6   \<0.0001   628    20.6
  TIA                             5             2.3           49            2.1                                           19            4.3    0.0127     73     2.4
  Systematic thromboembolism      3             1.4           23            1.0                                           19            4.2    \<0.0001   45     1.5
  Pulmonary thromboembolism       1             0.5           5             0.2                                           4             0.9    0.0695     10     0.3
  Deep vein thrombosis            0             0.0           17            0.7                                           11            2.4    0.0002     28     0.9
  Peripheral artery diseases      16            7.5           64            2.7                                           63            14.1   \<0.0001   143    4.7
  Dyslipidemia                    85            39.7          893           37.6                                          232           51.2   \<0.0001   1210   39.8
  Angina pectoris                 43            20.1          204           8.6                                           146           32.1   \<0.0001   393    12.9
  Myocardial infarction           11            5.1           67            2.8                                           82            18.1   \<0.0001   160    5.3
  Hepatic insufficiency           13            6.0           200           8.4                                           37            8.1    0.4639     250    8.2
  Renal insufficiency             25            11.8          429           18.8                                          112           25.7   0.0002     566    19.3
  Bleeding history                8             3.7           103           4.3                                           28            6.2    0.3625     139    4.6
                                                                                                                                                                 
  Creatinine clearance (mL/min)                                                                                                                                  
  Mean (SD)                       63.5 (27.6)   63.4 (25.9)   58.1 (23.7)   0.1080                                        62.7 (25.8)                            
                                                                                                                                                                 
  PT--INR                                                                                                                                                        
  Mean (SD)                       --            2.00 (0.44)   1.94 (0.44)   0.0350                                        1.99 (0.44)                            

AP, antiplatelet monotherapy; AC, anticoagulant monotherapy; TIA, transient ischemic attack; PT--INR, prothrombin time--international normalized ratio.

*P*-values were calculated by using the Cochran--Mantel--Haenszel test adjusted by sex and age for classification values, and ANOVA adjusted by sex and age for order (CHADS~2~ score) and measured (creatinine clearance and PT--INR) values.

###### 

Antiplatelet regimen at the point of a bleeding event and at the observational point.

Table 4

  **Antithrombotic regimens on bleeding events**   **Antithrombotic regimen at the observational point**   **Total**   Bowker׳s test                                          
  ------------------------------------------------ ------------------------------------------------------- ----------- --------------- -------- ---- -------- ----- --------- ------------
  AP                                               0                                                                   5               (4.6)    3    (2.8)    8     (7.3)     *P*=0.2643
  AC                                               3                                                       (2.8)       68              (62.4)   8    (7.3)    79    (72.5)    
  AP+AC                                            0                                                                   11              (10.1)   11   (10.1)   22    (20.2)    
  Subtotal                                         3                                                       (2.8)       84              (77.1)   22   (20.2)   109   (100.0)   
  No antithrombotics                               5                                                       (3.6)       19              (13.7)   6    (4.3)    30    (21.6)    

AP, antiplatelet monotherapy; AC, anticoagulant monotherapy.

###### 

Characteristics of patients in the AC and AP+AC groups.

Table 5

                                        N group       S group       P group       *P*-value[a](#tbl5fna){ref-type="table-fn"}   Total                                  
  ------------------------------------- ------------- ------------- ------------- --------------------------------------------- ------------- ------ ---------- ------ ------
  Total                                 328                         213                                                         2290                            2831   
  **Sex**                                                                                                                                                              
  Male                                  185           56.4          129           60.6                                          1549          67.6   \<0.0001   1863   65.8
  Female                                143           43.6          84            39.4                                          741           32.4              968    34.2
  **Age (years)**                                                                                                                                                      
  Mean (SD)                             74.0 (11.0)   74.0 (9.2)    74.1 (9.2)    0.3968                                        74.1 (9.4)                             
  \<65                                  66            20.1          31            14.6                                          343           15.0   0.7153     440    15.5
  65--\<75                              97            29.6          79            37.1                                          878           38.3              1054   37.2
  \>75                                  165           50.3          103           48.4                                          1069          46.7              1337   47.2
  **Body weight (kg)**                                                                                                                                                 
  Mean (SD)                             58.5 (12.9)   59.7 (11.1)   61.8 (12.3)   0.0018                                        61.2 (12.3)                            
  **BMI (kg/m**^**2**^**)**                                                                                                                                            
  Mean (SD)                             23.0 (3.7)    23.2 (3.4)    23.9 (3.6)    0.0008                                        23.7 (3.6)                             
  **Prevalence period of AF (years)**                                                                                                                                  
  Mean (SD)                             1.77 (2.78)   4.62 (3.11)   4.89 (3.01)   \<0.0001                                      4.50 (3.15)                            
  **Type of AF**                                                                                                                                                       
  Paroxysmal                            119           36.7          65            30.8                                          733           32.7   \<0.0001   917    33.0
  Persistent                            98            30.2          30            14.2                                          424           18.9              552    19.9
  Permanent                             107           33.0          116           55.0                                          1085          48.4              1308   47.1
  **Smoking history**                                                                                                                                                  
  Nonsmoker                             182           63.4          117           63.6                                          1236          60.9   0.1077     1535   61.4
  Ex-smoker                             72            25.1          55            29.9                                          617           30.4              744    29.8
  Smoker                                33            11.5          12            6.5                                           175           8.6               220    8.8
  **Alcohol consumption (g/week)**                                                                                                                                     
  None                                  174           62.1          108           60.3                                          1079          54.2   0.2907     1361   55.5
  \<14                                  30            10.7          23            12.8                                          229           11.5              282    11.5
  14--\<112                             45            16.1          31            17.3                                          371           18.6              447    18.2
  \>112                                 31            11.1          17            9.5                                           313           15.7              361    14.7

AP, antiplatelet monotherapy; AC, anticoagulant monotherapy; N, naïve (initiated within 6 months); S, switcher (switched within 6 months); P, prevalent user (continued for \>6 months); BMI, body mass index; AF, atrial fibrillation.

*P* values were calculated by using the Cochran--Mantel--Haenszel test adjusted by sex and age for classification (sex, type of AF, smoking history, and alcohol history) and order (age) values, and ANOVA adjusted by sex and age for measured (age, body weight, BMI, and prevalence periods of AF) and order (age) values.

###### 

CHADS~2~ score, comorbidity, and creatinine clearance in the AC and AP+AC groups.

Table 6

                                               N group       S group       P group       *P*-value[a](#tbl6fna){ref-type="table-fn"}   Total                                
  -------------------------------------------- ------------- ------------- ------------- --------------------------------------------- ------------- ------ -------- ------ ------
  Total                                        328                         213                                                         2290                          2831   
  **Risk classification (CHADS**~**2**~**)**                                                                                                                                
  Mean (SD)                                    2.1 (1.3)     2.2 (1.4)     2.2 (1.3)     0.4314                                        2.2 (1.3)                            
  0                                            24            7.3           24            11.3                                          187           8.3    0.3049   235    8.4
  1                                            92            28.1          42            19.7                                          531           23.5            665    23.7
  2                                            105           32.1          60            28.2                                          676           29.9            841    30.0
  3                                            52            15.9          48            22.5                                          516           22.8            616    22.0
  4                                            35            10.7          30            14.1                                          246           10.9            311    11.1
  5                                            18            5.5           8             3.8                                           78            3.4             104    3.7
  6                                            1             0.3           1             0.5                                           30            1.3             32     1.1
  **Comorbidity**                                                                                                                                                           
  Heart failure                                98            30.0          65            30.5                                          792           34.8   0.0539   955    33.9
  Hypertension                                 224           68.3          150           70.4                                          1555          68.1   0.8048   1929   68.3
  Diabetes                                     65            19.8          44            20.7                                          549           24.0   0.2425   658    23.3
  Stroke                                       68            20.7          51            23.9                                          474           20.7   0.4406   593    21.0
  TIA                                          8             2.5           5             2.3                                           55            2.4    0.9962   68     2.4
  Systematic thromboembolism                   3             0.9           5             2.3                                           34            1.5    0.4283   42     1.5
  Pulmonary thromboembolism                    0             0.0           0             0.0                                           9             0.4    0.3326   9      0.3
  Deep vein thrombosis                         3             0.9           1             0.5                                           24            1.1    0.5669   28     1.0
  Peripheral artery diseases                   20            6.2           4             1.9                                           103           4.6    0.0601   127    4.5
  Dyslipidemia                                 107           32.8          92            43.8                                          922           40.4   0.0088   1121   39.8
  Angina pectoris                              29            8.9           20            9.4                                           301           13.2   0.0558   350    12.4
  Myocardial infarction                        12            3.7           5             2.4                                           132           5.8    0.0714   149    5.3
  Hepatic insufficient                         24            7.3           17            8.0                                           194           8.5    0.8300   235    8.3
  Renal insufficient                           51            16.4          36            17.1                                          453           20.7   0.0833   540    19.9
  Dementia                                     30            9.1           9             4.2                                           129           5.6    0.0432   168    5.9
  History of hemorrhage                        8             2.4           20            9.4                                           103           4.5    0.0007   131    4.6
  **Creatinine clearance (mL/min)**                                                                                                                                         
  Mean (SD)                                    62.7 (26.7)   66.8 (20.6)   62.1 (26.0)   0.0694                                        62.7 (25.8)                          

AP, antiplatelet monotherapy; AC, anticoagulant monotherapy; N, naïve (initiated within 6 months); S, switcher (switched within 6 months); P, prevalent user (continued for \>6 months); TIA, transient ischemic attack.

*P*-values were calculated by using the Cochran--Mantel--Haenszel test adjusted by sex and age for classification values, and ANOVA adjusted by sex and age for order (CHADS~2~ score) and measured (creatinine clearance) values.

###### 

Daily doses of AC and PT--INR.

Table 7

                                           N group   S group   P group   Total   *P*-value[a](#tbl7fna){ref-type="table-fn"}
  -------------------------------- ------- --------- --------- --------- ------- ---------------------------------------------
  Daily dose of warfarin (mg)      *n*     216       53        2254      2523    0.0020
  Mean                             2.44    2.47      2.73      2.70              
  SD                               1.09    1.03      1.10      1.10              
                                                                                   
  PT--INR                          *n*     198       52        2205      2455    \<0.0001
  Mean                             1.83    2.01      2.00      1.99              
  SD                               0.47    0.44      0.43      0.44              
                                                                                   
  Daily dose of rivaroxaban (mg)   *n*     112       161       38        311     0.2652
  Mean                             12.50   11.96     12.50     12.22             
  SD                               2.51    2.45      2.53      2.49              

AC, anticoagulant monotherapy; N, naïve (initiated within 6 months); S, switcher (switched within 6 months); P, prevalent user (continued for \>6 months); PT--INR, prothrombin time--international normalized ratio.

*P* values were calculated by using ANOVA adjusted by sex and age for measured values.
